Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"Haematological toxicity"”.

  1. Targeted radiotherapy in metastatic neuroendocrine tumours: clinical and experimental studies

    … cure. Tumour response is variable and renal and haematological toxicity are dose-limiting side effects. In metastatic small intestinal NET (SI-NET) hepatic metastases are often a clinical problem. Several treatment options exist and radioembolization (RE) of the liver is a recently introduced …

    goteborg Repository record for Targeted radiotherapy in metastatic neuroendocrine tumours: clinical and experimental studies (opens in a new tab)

  2. Synthesis and pharmacological evaluation of novel anti-tumour prodrugs. Synthesis and pharmacological investigations into novel MMP-activated peptide-based prodrugs of methotrexate as potential cancer therapeutics

    … and osteosarcoma. A lack of selective tumour toxicity is one of the major problems associated with MTX chemotherapy, especially when given at high doses, as in high dose MTX (HDMTX) therapy. MTX causes various toxicity problems including life-threatening nephrotoxicity, haematological toxicity

    bradford Repository record for Synthesis and pharmacological evaluation of novel anti-tumour prodrugs. Synthesis and pharmacological investigations into novel MMP-activated peptide-based prodrugs of methotrexate as potential cancer therapeutics (opens in a new tab)

  3. Chemoptherapy Dose Reductions in Palliative Lung Cancer. Evaluating Chemotherapy Dose Reductions following Neutropenia in Palliative Lung Cancer to prevent further Adverse Events

    … is a life-threatening and dose-limiting toxicity of palliative lung cancer chemotherapy. Whilst some neutropenias are inevitable, evidence suggests that patients with a previous neutropenic event are 50% more likely to have a further neutropenic event. The aim of this research is to …

    bradford Repository record for Chemoptherapy Dose Reductions in Palliative Lung Cancer. Evaluating Chemotherapy Dose Reductions following Neutropenia in Palliative Lung Cancer to prevent further Adverse Events (opens in a new tab)

  4. Chemoptherapy Dose Reductions in Palliative Lung Cancer. Evaluating Chemotherapy Dose Reductions following Neutropenia in Palliative Lung Cancer to prevent further Adverse Events

    … is a life-threatening and dose-limiting toxicity of palliative lung cancer chemotherapy. Whilst some neutropenias are inevitable, evidence suggests that patients with a previous neutropenic event are 50% more likely to have a further neutropenic event. The aim of this research is to …

    bradford Repository record for Chemoptherapy Dose Reductions in Palliative Lung Cancer. Evaluating Chemotherapy Dose Reductions following Neutropenia in Palliative Lung Cancer to prevent further Adverse Events (opens in a new tab)